Rapid Micro Biosystems (NASDAQ:RPID) reported record results for both the fourth quarter and full year of 2025 on March 12, 2026, as strong demand for its Growth Direct platform drove higher product and recurring revenue.
Fourth-quarter revenue climbed 37% year-over-year to $11.3 million, while full-year revenue increased 20% to $33.6 million. Despite the revenue growth, the company recorded a wider quarterly net loss of $12.5 million.
The company pointed to strong commercial momentum during the year, including a record multi-system Growth Direct order from Amgen in late 2025 and another significant multi-system order from Samsung Biologics in early 2026.
Looking ahead, Rapid Micro Biosystems expects 2026 revenue to range between $37 million and $41 million. The company also anticipates improved gross margins and plans to install between 30 and 38 Growth Direct systems during the year, reflecting increasing global adoption of its technology even as the business continues to operate at a loss.
During 2025, the company installed 28 Growth Direct systems and achieved a modest positive gross margin for the full year. Operating expenses were tightly managed, although inventory write-offs weighed on margins in the fourth quarter.
Rapid Micro Biosystems ended 2025 with approximately $39 million in cash and an additional $25 million available under an undrawn debt facility. The company said this liquidity will support its strategy of expanding system placements, improving margins and advancing new product development as major biopharmaceutical companies increasingly adopt its automation platform.
More about Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. is a life sciences technology company that develops automation solutions designed to improve manufacturing efficiency and accelerate the safe release of healthcare products. Its technology is used in the production of biologics, vaccines, cell and gene therapies and sterile injectable medicines.
The company’s flagship Growth Direct system automates microbial quality control testing for large pharmaceutical manufacturing operations. By modernizing testing processes and bringing quality control closer to the manufacturing floor, the platform aims to improve speed, accuracy, regulatory compliance and overall operational efficiency.